Pfizer Inc PFE

$27.82 -0.18 (-0.64%)

Valuation

Market cap
159,590,864,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.02
Forward PE
9.24
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
44,433,400
Avg volume
35,740,172
Day's range
$27.48 – $28.00
Shares out
5,699,674,000
Stochastic %K
38%
Beta
0.32
Analysts
Sell
Price target
$29.06

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Agent8 Oct 9, 6:58 AM
$PFE “For investors, this update signals that Pfizer is pushing deeper into chronic metabolic and sleep-related care, an area that has drawn strong interest due to rising obesity and sleep apnea rates. Success could create a new revenue stream, support sentiment around PFE’s post-pandemic pipeline, and add another angle of competition to a crowded obesity and cardiometabolic field led by players like Eli Lilly and Novo Nordisk.” https://www.tipranks.com/news/company-announcements/pfizers-vesper-osa-1-trial-targets-sleep-apnea-and-obesity-with-monthly-shot#google_vignette LT
0 replies
GPTInsights Oct 9, 3:27 AM
$VKTX $PFE I wonder if Bourla stays up at night regretting buying metsera the way I have been this week regretting buying viking
0 replies
skiddy5 Oct 9, 1:31 AM
$T $TMUS $V all of these are no growth, debt ridden dinosaurs. Capex to maintain and grow insane. Debt loads in high rate environment = pukefest. Margins going to erode with new satellite players (space guys) . If you want no growth but want safe yields without debt just try $TLT or $PFE . No idea why anyone would own this space here.
0 replies
KryptonResearch14 Oct 8, 7:36 PM
$PFE Pfizer picked up an FDA label expansion yesterday: TUKYSA plus trastuzumab and pertuzumab as maintenance treatment for HER2-positive metastatic breast cancer after induction therapy. The HER2CLIMB-05 numbers: median progression-free survival 24.9 months vs 16.3 on placebo, with the risk of progression or death cut 35.9 percent (hazard ratio 0.64, 654 patients). What changes is the setting. Tukysa has been a later-line drug since its 2020 approval. It now moves into frontline maintenance as a chemotherapy-free option, which means earlier access to patients in the metastatic pathway. Second pipeline note this week: LITFULO posted Phase 3 vitiligo data, 21.86 percent facial repigmentation on 100mg vs 2.40 percent on placebo at week 52, with FDA and EMA filings planned. That would be a second indication for a drug already approved for alopecia areata.
0 replies
TraderDaKing Oct 8, 6:05 PM 1 replies
nimii Oct 8, 2:13 PM
$PFE 😡😤
0 replies
Makingmillions192 Oct 8, 2:11 PM
$PFE GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications. 💊 https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/glp-1-weight-loss%2fdiabetes-industries-continue-transition-to-oral-me-1233250
0 replies
StocktwitsNews Oct 8, 1:35 PM
PFE, LLY, MRK Stocks In Focus: Cantor Raises Price Targets On Pharma Behemoths, But Flags Growth Concerns For Pfizer $LLY $MRK $PFE https://stocktwits.com/news/equity/markets/pfe-lly-mrk-stocks-in-focus-cantor-raises-price-targets/cZDUjtoRBNS
0 replies